Can I Take CoQ10 with Sermorelin?
At a glance
- CoQ10 interactions flagged by NCCIH / warfarin, insulin, some cancer treatments [1]
- CoQ10 safety / no serious side effects reported; observed safe level 1,200 mg/day [1][7]
- CoQ10 doses in trials / 50 mg twice daily up to 600 mg/day ubiquinol [8][9]
- Blood pressure effect / not significant in pooled randomized trials [10]
- Sermorelin today / compounded, not FDA-approved; Geref withdrawn in 2009 [4][11]
Is there a known interaction between CoQ10 and sermorelin?
The two are described very differently. CoQ10 is a substance the body makes, with the highest levels in the heart, liver, kidneys and pancreas, and it is sold in the United States as a dietary supplement [1]. Its described jobs are electron transport in mitochondrial energy production and lipid-phase antioxidant activity [12]. Sermorelin is a peptide that acts on the pituitary to trigger the body's own growth hormone release; it is not growth hormone itself [3].
Sermorelin: a peptide with no current FDA approval
Sermorelin is a 29-amino-acid analogue of human growth hormone-releasing hormone, the shortest synthetic peptide with the full biological activity of GHRH [3]. In healthy men given GHRH(1-29)-NH2 intravenously, the peptide was eliminated quickly, yet growth hormone levels stayed raised for about 3 hours [13].
Sermorelin was once approved as Geref under two applications: a 0.05 mg/ampule product for testing the pituitary's ability to secrete growth hormone, approved December 28, 1990, and 0.5 mg and 1 mg vials for treating idiopathic growth hormone deficiency in children with growth failure, approved September 26, 1997 [4]. The manufacturer discontinued both in 2008 and asked FDA to withdraw the applications, which FDA did effective June 18, 2009 [4]. In March 2013 FDA determined that Geref was not withdrawn for reasons of safety or effectiveness [4]. The approved uses never included adults, anti-aging, weight loss or athletic performance [4].
With the approval gone, sermorelin products sold in the US today are compounded, and compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [11]. Sermorelin is not on FDA's list of bulk substances that may present significant safety risks when compounded [14]. HealthRX.com offers sermorelin by prescription.
What CoQ10 is, and what its own data show
CoQ10 is naturally present in the body and is sold as a supplement; a Drugs@FDA search for ubidecarenone returned no approved drug application [1][2].
NCCIH reports no serious side effects, with mild effects such as insomnia or digestive upset possible [1]. A formal risk assessment found that nausea and other stomach effects were no more common at 1,200 mg/day than at 60 mg/day, and set 1,200 mg/day as the observed safe level; data above that dose are not sufficient to conclude safety [7].
Doses used in the trials cited on this page were 100 mg/day for 4 weeks in a warfarin study [6], 50 mg twice daily for 30 days [8], 400 mg/day for 8 weeks [16], and 600 mg/day as ubiquinol for 8 weeks [9]. These are study doses, not recommended doses.
NCCIH also states that CoQ10 may interact with warfarin and with insulin, and may not be compatible with some types of cancer treatment; its page gives no detail on the insulin or cancer-treatment points [1].
CoQ10 and warfarin: what the reports show
Case reports describe a reduced warfarin response with CoQ10. A 72-year-old woman on warfarin became less responsive while taking CoQ10 and returned to her previous response when she stopped it; CoQ10 is chemically similar to vitamin K, which was offered as a possible explanation [5]. A 1994 Lancet letter is titled 'Reduced effect of warfarin caused by ubidecarenone' [17].
The best controlled human data point the other way. In a randomized, double-blind, placebo-controlled crossover trial, 24 outpatients on stable long-term warfarin took CoQ10 100 mg/day for 4 weeks; INR stayed stable and the geometric mean warfarin dose was 36.5 mg/week on CoQ10 versus 36.0 mg/week on placebo, with 21 patients completing [6]. So the case reports suggest it can happen in some people, while the controlled trial at 100 mg/day found no change in INR control or warfarin dose [5][6].
CoQ10 and blood pressure
CoQ10 does not appear to be a meaningful blood pressure treatment. Cochrane pooled two randomized trials in 50 people with hypertension and found a systolic change of -3.68 mmHg (95% CI -8.86 to 1.49) and a diastolic change of -2.03 mmHg (95% CI -4.86 to 0.81), neither significant, with moderate-quality evidence of no clinically significant effect [10]. NCCIH says CoQ10 probably has no meaningful effect on blood pressure [1].
What the sermorelin safety data cover
The safety data for sermorelin come mainly from children with growth hormone deficiency. In a 1-year, open-label, multicenter study of 110 previously untreated prepubertal children, no adverse changes appeared in general biochemistry or hormone tests, fasting glucose did not change, IGF-I was not excessively raised, and the peptide was well tolerated overall [19]. That is the population and duration the data cover; it is not an adult safety database.
CoQ10's known interaction flags are warfarin, insulin and some cancer treatments [1]. Those are CoQ10's own interactions, not interactions with sermorelin.
Frequently asked questions
Can I take CoQ10 with sermorelin?
Does CoQ10 lower blood pressure?
Is CoQ10 safe at supplement doses?
Does CoQ10 interact with statins?
Is sermorelin FDA-approved?
References
Show all 24 referencesHide references
- Coenzyme Q10 | NCCIH.
- Drugs@FDA: FDA-Approved Drugs.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
- Federal Register :: Request Access.
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger. 1998;160(22):3226-7.
- Engelsen J, Nielsen JD, Hansen KF. [Effect of Coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger. 2003;165(18):1868-71.
- Hathcock JN, Shao A. Risk assessment for coenzyme Q10 (Ubiquinone). Regul Toxicol Pharmacol. 2006;45(3):282-8.
- Skarlovnik A, Janić M, Lunder M, Turk M, Šabovič M. Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study. Med Sci Monit. 2014;20:2183-8.
- Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015;238(2):329-35.
- Ho MJ, Li EC, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev. 2016;3(3):CD007435.
- Official web page.
- Garrido-Maraver J, Cordero MD, Oropesa-Avila M, Vega AF, de la Mata M, Pavon AD, et al. Clinical applications of coenzyme Q10. Front Biosci (Landmark Ed). 2014;19(4):619-33.
- Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-5.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Kalén A, Appelkvist EL, Dallner G. Age-related changes in the lipid compositions of rat and human tissues. Lipids. 1989;24(7):579-84.
- Dohlmann TL, Kuhlman AB, Morville T, Dahl M, Asping M, Orlando P, et al. Coenzyme Q10 Supplementation in Statin Treated Patients: A Double-Blinded Randomized Placebo-Controlled Trial. Antioxidants (Basel). 2022;11(9).
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet. 1994;344(8933):1372-3.
- Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. 2007;21(4):297-306.
- Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
- Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.
- Langsjoen PH, Langsjoen AM. Comparison study of plasma coenzyme Q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone. Clin Pharmacol Drug Dev. 2014;3(1):13-7.
- Banach M, Serban C, Sahebkar A, Ursoniu S, Rysz J, Muntner P, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90(1):24-34.
- Kennedy C, Köller Y, Surkova E. Effect of Coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: A systematic review and meta-analysis. Atherosclerosis. 2020;299:1-8.
- Qu H, Guo M, Chai H, Wang WT, Gao ZY, Shi DZ. Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2018;7(19):e009835.